BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35822679)

  • 1. Immunosuppressive Effects and Potent Anti-tumor Efficacy of mTOR Inhibitor Everolimus in Breast Tumor-bearing Mice.
    Rostamzadeh D; Haghshenas MR; Samadi M; Mojtahedi Z; Babaloo Z; Ghaderi A
    Iran J Allergy Asthma Immunol; 2022 Jun; 21(3):287-299. PubMed ID: 35822679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor Progression Locus 2 (Tpl2) Activates the Mammalian Target of Rapamycin (mTOR) Pathway, Inhibits Forkhead Box P3 (FoxP3) Expression, and Limits Regulatory T Cell (Treg) Immunosuppressive Functions.
    Li X; Acuff NV; Peeks AR; Kirkland R; Wyatt KD; Nagy T; Watford WT
    J Biol Chem; 2016 Aug; 291(32):16802-15. PubMed ID: 27261457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with mTOR inhibitors after liver transplantation enables a sustained increase in regulatory T-cells while preserving their suppressive capacity.
    Ghazal K; Stenard F; Dahlqvist G; Barjon C; Aoudjehane L; Scatton O; Conti F
    Clin Res Hepatol Gastroenterol; 2018 Jun; 42(3):237-244. PubMed ID: 29175009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oscillatory mTOR inhibition and Treg increase in kidney transplantation.
    Sabbatini M; Ruggiero G; Palatucci AT; Rubino V; Federico S; Giovazzino A; Apicella L; Santopaolo M; Matarese G; Galgani M; Terrazzano G
    Clin Exp Immunol; 2015 Nov; 182(2):230-40. PubMed ID: 26077103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A matrix metalloproteinase inhibitor enhances anti-cytotoxic T lymphocyte antigen-4 antibody immunotherapy in breast cancer by reprogramming the tumor microenvironment.
    Li M; Xing S; Zhang H; Shang S; Li X; Ren B; Li G; Chang X; Li Y; Li W
    Oncol Rep; 2016 Mar; 35(3):1329-39. PubMed ID: 26752000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus combined with PD-1 blockade inhibits progression of triple-negative breast cancer.
    Li G; Hu J; Cho C; Cui J; Li A; Ren P; Zhou J; Wei W; Zhang T; Liu X; Liu W
    Cell Signal; 2023 Sep; 109():110729. PubMed ID: 37257766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interplay between mTOR and STAT5 signaling modulates the balance between regulatory and effective T cells.
    Shan J; Feng L; Sun G; Chen P; Zhou Y; Xia M; Li H; Li Y
    Immunobiology; 2015 Apr; 220(4):510-7. PubMed ID: 25468562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations of different immune checkpoints-expressing CD4
    Al-Mterin MA; Murshed K; Alsalman A; Abu-Dayeh A; Elkord E
    BMC Cancer; 2022 Jun; 22(1):601. PubMed ID: 35655158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-15 gene therapy and the mammalian target of rapamycin inhibitor everolimus inhibit the growth of metastatic breast cancer.
    Zhao N; Li X; He X; Qiu Y; Zhu L; Qi F
    J Gene Med; 2013 Oct; 15(10):366-74. PubMed ID: 24038990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells.
    Yunokawa M; Koizumi F; Kitamura Y; Katanasaka Y; Okamoto N; Kodaira M; Yonemori K; Shimizu C; Ando M; Masutomi K; Yoshida T; Fujiwara Y; Tamura K
    Cancer Sci; 2012 Sep; 103(9):1665-71. PubMed ID: 22703543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells.
    Zeiser R; Leveson-Gower DB; Zambricki EA; Kambham N; Beilhack A; Loh J; Hou JZ; Negrin RS
    Blood; 2008 Jan; 111(1):453-62. PubMed ID: 17967941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mangiferin Attenuates Murine Lupus Nephritis by Inducing CD4+Foxp3+ Regulatory T Cells via Suppression of mTOR Signaling.
    Liang CL; Lu W; Zhou JY; Chen Y; Zhang Q; Liu H; Qiu F; Dai Z
    Cell Physiol Biochem; 2018; 50(4):1560-1573. PubMed ID: 30359968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-1R1 is expressed on both Helios(+) and Helios(-) FoxP3(+) CD4(+) T cells in the rheumatic joint.
    Müller M; Herrath J; Malmström V
    Clin Exp Immunol; 2015 Oct; 182(1):90-100. PubMed ID: 26076982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer.
    Yardley DA; Liggett W; Mainwaring M; Castrellon A; Blakely L; Hemphill B; Anz B; Young RR; Shastry M; DeBusk LM; Hainsworth JD; Burris HA
    Clin Breast Cancer; 2020 Apr; 20(2):89-97. PubMed ID: 31932237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of SLC administration and Tregs depletion is an attractive strategy for targeting hepatocellular carcinoma.
    Chen L; Zhou S; Qin J; Hu H; Ma H; Liu B; Wang X; Ma J; Ye S; Zhong C; Zhou G; Liang C
    Mol Cancer; 2013 Dec; 12(1):153. PubMed ID: 24304581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methionine enkephalin (MENK) inhibits tumor growth through regulating CD4+Foxp3+ regulatory T cells (Tregs) in mice.
    Li X; Meng Y; Plotnikoff NP; Youkilis G; Griffin N; Wang E; Lu C; Shan F
    Cancer Biol Ther; 2015; 16(3):450-9. PubMed ID: 25701137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered frequency of CD8
    Rostamzadeh D; Haghshenas MR; Daryanoosh F; Samadi M; Hosseini A; Ghaderi A; Mojtahedi Z; Babaloo Z
    J Cell Physiol; 2019 Jul; 234(7):11986-11998. PubMed ID: 30623416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunosuppressive drugs on inducing Ag-specific CD4(+)CD25(+)Foxp3(+) Treg cells during immune response in vivo.
    Wu T; Zhang L; Xu K; Sun C; Lei T; Peng J; Liu G; Wang R; Zhao Y
    Transpl Immunol; 2012 Aug; 27(1):30-8. PubMed ID: 22613676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell Immunity.
    Beziaud L; Mansi L; Ravel P; Marie-Joseph EL; Laheurte C; Rangan L; Bonnefoy F; Pallandre JR; Boullerot L; Gamonet C; Vrecko S; Queiroz L; Maurina T; Mouillet G; Hon TN; Curtit E; Royer B; Gaugler B; Bayry J; Tartour E; Thiery-Vuillemin A; Pivot X; Borg C; Godet Y; Adotévi O
    Cancer Res; 2016 Jul; 76(14):4100-12. PubMed ID: 27197194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing the Effects of the mTOR Inhibitors Azithromycin and Rapamycin on In Vitro Expanded Regulatory T Cells.
    Bergström M; Müller M; Karlsson M; Scholz H; Vethe NT; Korsgren O
    Cell Transplant; 2019 Dec; 28(12):1603-1613. PubMed ID: 31512504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.